Dr. Sarah Jarvis, a London-based GP with a special interest in cardiology, joined Professor Terry McCormack, a GP and Honorary Professor in Primary Care Cardiovascular Medicine at the Hull York Medical School, to discuss how bleeding risk should influence your treatment decision-making for stroke prevention in non-valvular atrial fibrillation (NVAF).
Introducing Jenny, Tom and Adhar, our experts use these patient examples to determine the key factors when considering treatment options for stroke prevention in patients with NVAF. These include:
- The role of CHA2DS2-VASc and HAS-BLED in determining stroke and bleeding risk
- What the guidelines recommend for managing anticoagulation for stroke prevention in patients with NVAF, particularly in light of the COVID-19 pandemic
- There are four currently available non-vitamin K antagonist oral anticoagulants (NOACs), with different criteria for dose reduction
- A review of the number of patients on low-dose NOACs in clinical trials and the percentage of real-world prescriptions of low-dose NOACs in the UK
- The efficacy and safety outcomes for the low-dose NOACs in the pivotal Phase III clinical trials comparing NOACs vs warfarin
- The availability of a specific reversal agent for emergency surgery or life-threatening bleeding.
Below, hear our experts outline why not all patients with NVAF are the same and the need for a tailored approach to stroke prevention.
NOAC — non-vitamin K antagonist oral anticoagulant
NVAF — non-valvular atrial fibrillation